Core Viewpoint - The surge in IPO applications from 18A companies in Hong Kong is driven by a pent-up demand for listings, but only a small fraction will successfully go public due to market conditions and company quality [1][2][8] Group 1: IPO Market Dynamics - The number of 18A companies applying for IPOs has doubled compared to the entire year of 2024, with 11 companies submitting applications in November alone [1][4] - Despite the high number of applications, only about 15 out of over 70 companies that applied this year have successfully listed, indicating a significant bottleneck in the IPO process [1][8] - The current market sentiment is volatile, with a recent downturn in the secondary market affecting the IPO landscape, reminiscent of previous downturns in 2022 and 2018 [1][8] Group 2: Market Sentiment and Investment Climate - The recent IPO frenzy is a response to improved market conditions and supportive policies for innovative drugs, leading to a resurgence in applications from biotech firms [2][3] - Major IPOs, such as that of Ying'en Biotech, have significantly boosted market confidence, with its first-day closing price reflecting a 116% increase [2][3] - The secondary market has shown signs of recovery, but the enthusiasm may not be sustainable, as many companies lack the quality needed to succeed in the current environment [8][10] Group 3: Challenges Facing Biotech Companies - Many biotech firms are under financial pressure due to prolonged fundraising difficulties and high clinical trial costs, leading to a critical need for IPOs as a means of survival [6][7] - The current IPO landscape is characterized by a harsh selection process, with many companies facing extended waiting times that could exacerbate their financial struggles [8][10] - The cautious approach of investors in the primary market reflects a shift towards prioritizing companies with proven commercialization capabilities, making it harder for those relying solely on narratives to attract funding [10][11]